Enveric Biosciences, Inc.
@Enveric_Bio
Followers
3K
Following
888
Media
652
Statuses
2K
Enveric Biosciences (NASDAQ: $ENVB), a new approach to solving mental health challenges.
Naples
Joined June 2020
Once issued, claims covered by the new U.S. patent will further broaden Enveric’s pipeline by covering additional potential neuroplastogenic non-hallucinogenic molecules & strengthening its potential to target neuropsychiatric & addiction disorders. https://t.co/2J4YOcp2ih $ENVB
2
1
2
Enveric has received a Notice of Allowance from the USPTO for a patent application pertaining to its EVM301 Series of molecules being developed as potential treatments for mental health disorders. For more info, visit: https://t.co/2J4YOcp2ih $ENVB
1
2
2
Enveric's EVM401 IP expansion along with Delix's FDA clearance for a Ph II trial of DLX-001 suggest a growing confidence in non-hallucinogenic neuroplastogens that have the potential to transform how neuropsychiatric disorders are treated. Read more: https://t.co/0m0GQ3o2lg $ENVB
1
1
2
Meditech Today highlights the growing validation & regulatory support for non-hallucinogenic neuroplastogens, which have the potential to make psychedelic-like benefits more practical & accessible for those suffering from neuropsychiatric disorders. https://t.co/8FLyGJLU96 $ENVB
meditechtoday.com
How neuroplastogens became the next frontier.
0
1
2
Enveric will present & participate in the Sachs Associates 9th Annual Neuroscience Innovation Forum on Jan 11, 2026 during “J.P. Morgan Week 2026”. Additionally, Enveric will attend #BiotechShowcase 2026, being held January 12-14. https://t.co/GtYrxF5lWi $ENVB #JPM2026
0
1
3
Dr. Joseph Tucker, shared insights with @AuthorityMgzine on how to best heal the broken mental health system & highlighted the potential of Enveric’s non-hallucinogenic neuroplastogen EB-003 to provide hope to people suffering from depression & anxiety. https://t.co/KmSSf0moZY
0
1
2
Our CEO, Joseph Tucker, Ph.D., comments on the Company's new notice of allowance from the USPTO for its EVM401 series of drug candidates. Learn more here: https://t.co/xYUMfHIrug $ENVB
1
1
1
Claims covered by Enveric's new U.S. patent will further broaden the Company's pipeline by covering additional potential neuroplastogenic non-hallucinogenic molecules and strengthening its potential to target neuropsychiatric and addiction disorders. https://t.co/xYUMfHIrug $ENVB
0
1
2
Enveric has received a Notice of Allowance from the United States Patent and Trademark Office for a patent application pertaining to its EVM401 Series of molecules being developed as potential treatments for mental health disorders. For more info, visit: https://t.co/xYUMfHIrug
0
1
2
In Q3, Enveric continued toward clinical readiness for EB-003, targeting neuropsychiatric indications, announcing positive data in a preclinical model of PTSD, successful completion of dose range finding studies, & FDA response to pre-IND meeting request. https://t.co/LmDNYtTh4O
0
1
2
Enveric has announced financial results for the third quarter ended September 30, 2025, and provided a comprehensive business update. See it here: https://t.co/LmDNYtTh4O $ENVB
0
1
1
Enveric is developing its neuroplastogen, EB-003, to overcome the limitations of current psychedelic-based treatments. EB-003 has the potential to promote neuroplasticity without hallucinations, making treatment more scalable & clinically practical. https://t.co/TVzfrj3a0s $ENVB
1
1
3
Many neuropsychiatric disorders are increasingly linked to impaired brain connectivity. Enveric’s, EB-003, has the potential to promote neuroplasticity without hallucinations to address mental health disorders including PTSD, depression & anxiety. https://t.co/TVzfrj3a0s $ENVB
3
4
8
Enveric is advancing toward the submission of its IND application for EB-003 which is expected in early 2026. Learn how Enveric is preparing for its IND from our CEO, Joseph Tucker's, recent conversation with Clinical Leader here: https://t.co/wLCLZ5Niz2 $ENVB
1
1
2
A new @microdosehq article highlights Enveric’s hiring of @FishRichardson to contest a Post-Grant Review petition filed by Gilgamesh Pharmaceuticals against the Company's issued '276 patent, which appears relevant to the Bretisilocin molecule. Read it here:
microdose.buzz
Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is...
0
1
2
Our CEO, Joseph Tucker, Ph.D., comments on the Company's 23rd issued U.S. patent for novel neuroplastogen molecules. For more info, visit: https://t.co/IB2CjhCqvM $ENVB
0
1
2
Enveric's newly announced patent covers a unique series of compounds, which are designed to target key serotonin receptors and drive neuroplasticity. Learn more: https://t.co/IB2CjhCqvM $ENVB
0
0
2
Enveric today announced the issuance of its 23rd patent from the USPTO for novel compounds within its neuroplastogenic patent estate, further expanding its intellectual property assets for the potential treatment of mental health disorders. More info https://t.co/IB2CjhCqvM $ENVB
0
1
1
"Enveric will vigorously defend its intellectual property and take all steps necessary to maximize the value of its intellectual property for shareholders,” Dr. Tucker, comments on the Company's hiring of @FishRichardson to defend its '276 patent. https://t.co/zI1K8zs7qb $ENVB
1
1
1